Jichuan Pharmaceutical: The cooperative product Masese Lovashawi Tablets has obtained a drug registration certificate.

Jichuan Pharmaceuticals announced that its wholly-owned subsidiary Jichuan Limited, in cooperation with Nanjing Zhengxiang Pharmaceuticals, has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the development of Marixiloxam tablets. This drug is a class 1 new drug, a new generation of polymerase acidic protein nucleic acid endonuclease inhibitor with broad-spectrum anti-influenza virus properties. It is approved for the treatment of adult patients with uncomplicated influenza A and B who are otherwise healthy. The approval of this collaborative product is expected to have a positive impact on the company's future development, but the listing of the drug will need to go through the market development cycle and may be affected by factors such as pharmaceutical industry policies, tender procurement, and uncertainties.